
Nanomedicine in Translational Research
Status and Future Challenges
- 1st Edition - September 17, 2024
- Imprint: Academic Press
- Editors: Kaladhar Kamalasanan, Chandra P. Sharma
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 2 2 2 5 7 - 3
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 2 2 5 8 - 0
Nanomedicine in Translational Research: Status and Future Challenges harnesses the current developments and future directions of diagnostic and therapeutic solutions in cli… Read more
Purchase options

Institutional subscription on ScienceDirect
Request a sales quoteNanomedicine in Translational Research: Status and Future Challenges harnesses the current developments and future directions of diagnostic and therapeutic solutions in clinical scenarios. This book integrates nanomedicine and biomaterials to develop healthcare technology for improved patient care and clinical practices, through applications using theranostics, biomaterials, 3-D printing, regenerative medicines, and nanosystems.
Those in this multidisciplinary field will need to improve procedures and protocols, as well as regulatory guidelines and their clinical implications. This book will be highly useful as it is written by experts in the field for researchers working in the areas of nanotechnology, biomaterials, drug delivery, and pharmaceuticals for chronic diseases.
- Focuses on the pillars contributing to the global healthcare crisis: geopolitical changes, overpopulation/migration, and climate change.
- Includes personal interviews with many world leaders in different areas along with the authors’ hands-on experience on healthcare, especially during the COVID-19 pandemic, for drafting the contents that confirm advanced healthcare.
- Provides a broad and multidisciplinary understanding of healthcare, allowing the readers to understand their role and empower them to take initiatives to emerging solutions.
Researchers working in the areas of nanotechnology, biomaterials, drug delivery and pharmaceuticals for generating the basic idea / strategies of developing viable future technologies for both acute and chronic diseases, Researchers, doctors/practitioners working in the areas of clinical fields and molecular biology. Also, it will be of interesting to the field of biotechnology, cell therapeutics and tissue engineering.
- Introduction
- Properties of biomaterials at nano range
- In vitro systems to demonstrate the nano effect
- Toxicology of biomaterials at nanoscale
- Porphyrinoid-based single molecule to nano theranostics towards personalized diagnosis and treatment
- Nanomaterials for biomedical applications
- Nanosystems - combination products
- Biomass derived carbon nanodots
- Nanosystems for Pharmaceutical applications
- Scope of Biomaterials for theranostics application
- Redox Nanotherapeutics: Fundamentals and Applications
- Smart Therapeutics: Evolution from small biomolecules to synthetic cells
- Applications of Artificial Intelligence and Machine Learning Models in Nanotherapeutics.
- Nanomedicine in Patient-specific Clinical Trend: Shape memory polymers of emerging biomedical applications and their future prospects
- Commercialized nanomedicines until to date
- Nanosystems development, Quality Control requirements and ethical issues
- Affordable and accessible nanomedicines: Regulatory perspectives from right to health
- Edition: 1
- Published: September 17, 2024
- No. of pages (Paperback): 426
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780443222573
- eBook ISBN: 9780443222580
KK
Kaladhar Kamalasanan
Dr. Kamalasanan is a Professor in the Department of Pharmaceutics, Amrita School of Pharmacy. He is the lead author of Roadmap for Biomaterials in Vision 2035 document by TIFAC, DST, India. He is an Industrial Pharmacist from Annamalai University and got trained in Biomaterials and Biomedical Engineering under Dr. Chandra P. Sharma at SCTIMST. He got trained in immunology under Prof. Harald Renz at Philipps University in Marburg, Germany. Later, he did three-year postdoctoral research with Dr. Steven R Little in interdisciplinary areas of immunotherapeutics, nanotechnology, and drug delivery at McGowan Institute for Regenerative Medicine and the Department of Chemical Engineering, Bioengineering, and Immunology, University of Pittsburgh, USA. After returning to India, he served as Chitra High Value Fellow Scientist-D at SCTIMST, India, for three years before moving to Amrita School of Pharmacy at Kochi, and is currently consulting for various organizations nationally and internationally. Dr. Kamalasanan has developed products that reached market filed several national and international patents, received numerous awards, and has several research articles, book chapters, and conference proceedings. He also actively participated in various professional society activities and has nearly 2 decades of research, technology development, and academic experience in translational medicine.
CS